RIGL
Rigel Pharmaceuticals, Inc.Healthcare · $908M market cap
Verdict
We can't put a fair value on RIGL right now. The financial data we receive for it contains an obvious error (its equity or assets jump more than 100× in one year). We'll value it once the data is corrected.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow RIGL
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases and 8 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Schorno Dean L
EVP & Chief Financial Officer · 2026-09-02
Option exercise
$31K
Schorno Dean L
EVP & Chief Financial Officer · 2026-09-02
Option exercise
$48K
Schorno Dean L
EVP & Chief Financial Officer · 2026-09-02
Option exercise
$12K
Schorno Dean L
EVP & Chief Financial Officer · 2026-09-02
Option exercise
$9K
Furey Raymond J.
EVP, GC, CCO & Corp Sec · 2026-09-01
Tax withholding
$42K
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works